TBPH - חוב כולל להון Theravance Corp

Theravance Biopharma generates revenue from Yupelri royalties and the development of orphan drugs. The operating model relies on the full outsourcing of production and clinical trials. Diversified medical hubs ensure supply stability. The GURU.Markets platform transmits the total financial debt-to-equity ratio, where 0.24 captures the current state of the parameter, demonstrating the business's leverage level.

This ratio measures the proportion of borrowed funds relative to equity, determining the business's degree of financial autonomy. It serves as a stress-testing tool for the company's resilience to changes in debt service costs. By analyzing the total debt-to-equity chart, an investor assesses the risk of bankruptcy. For Theravance Biopharma (TBPH), this balance is critical when scaling sales of the drug YUPELRI. Sufficient capital ensures the development of respiratory therapy without an excessive credit burden.